Biological and clinical relevance of miRNA expression signatures in primary plasma cell leukemia.
about
MicroRNAs and Chinese Medicinal Herbs: New Possibilities in Cancer TherapyMolecular Classification and Pharmacogenetics of Primary Plasma Cell Leukemia: An Initial Approach toward Precision MedicinePrimary plasma cell leukemia 2.0: advances in biology and clinical management.Global miRNA expression analysis identifies novel key regulators of plasma cell differentiation and malignant plasma cell.MicroRNA: important player in the pathobiology of multiple myelomaMicroRNA-330-3p promotes cell invasion and metastasis in non-small cell lung cancer through GRIA3 by activating MAPK/ERK signaling pathway.The miR-125a and miR-320c are potential tumor suppressor microRNAs epigenetically silenced by the polycomb repressive complex 2 in multiple myelomaA 3-miRNA signature predicts prognosis of pediatric and adolescent cytogenetically normal acute myeloid leukemia.Whole-exome sequencing of primary plasma cell leukemia discloses heterogeneous mutational patterns.A microRNA signature profile in EBV+ diffuse large B-cell lymphoma of the elderly.Identification of circulating microRNA signatures for upper tract urothelial carcinoma detection.Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo.Genome-wide pharmacologic unmasking identifies tumor suppressive microRNAs in multiple myeloma.Identification of Long Non-Coding RNAs Deregulated in Multiple Myeloma Cells Resistant to Proteasome Inhibitors.In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells.EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions.The potential of miRNAs as biomarkers for multiple myeloma.Mir-34: a new weapon against cancer?miR-23b/SP1/c-myc forms a feed-forward loop supporting multiple myeloma cell growth.MicroRNA expression patterns and target prediction in multiple myeloma development and malignancy.Mir-221/222 are promising targets for innovative anticancer therapy.Primary Plasma Cell Leukemia: Identity Card 2016.Jak3, STAT3, and STAT5 inhibit expression of miR-22, a novel tumor suppressor microRNA, in cutaneous T-Cell lymphomamiR-330-3p controls cell proliferation by targeting early growth response 2 in non-small-cell lung cancer.Analysis of miRNA, mRNA, and TF interactions through network-based methods.Epigenetic modifications in multiple myeloma: recent advances on the role of DNA and histone methylation.Pharmacokinetics and Pharmacodynamics of a 13-mer LNA-inhibitor-miR-221 in Mice and Non-human Primates.Disentangling the microRNA regulatory milieu in multiple myeloma: integrative genomics analysis outlines mixed miRNA-TF circuits and pathway-derived networks modulated in t(4;14) patients.Integrated analysis of microRNAs, transcription factors and target genes expression discloses a specific molecular architecture of hyperdiploid multiple myelomaThe effect of miR-146a on STAT1 expression and apoptosis in acute lymphoblastic leukemia Jurkat cells.MiR-330-3p inhibits gastric cancer progression through targeting MSI1.miR-497 expression, function and clinical application in cancer.Liquid biopsies for liquid tumors: emerging potential of circulating free nucleic acid evaluation for the management of hematologic malignanciesLenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia.A functional polymorphism in the miR-146a gene is associated with the risk of childhood acute lymphoblastic leukemia: a preliminary report.Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma.Role of miR-483 in digestive tract cancers: from basic research to clinical value.A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells.Plasma cell leukemia: update on biology and therapy.
P2860
Q26797487-4B89D239-23AB-421E-B131-7228E7BE95DFQ26799238-B0F86B50-FEF2-43D9-B70B-D3637B4CBF63Q30243927-84500900-EFA0-4206-B784-07A3468B2435Q33741100-2C19532D-F7A2-4976-894B-95500D772ED8Q33786861-AA505568-608A-48F5-9EC2-4A593BFCF8D4Q33814564-978A04FC-DD39-4BBC-9CBA-E853E7DC9730Q33838260-0B226D1C-3997-4C8D-B947-D17740740FD6Q33889001-CAE36911-46CF-4C1B-9B66-7DCC1CF40D22Q34479418-4770E96B-FF30-4CD7-A57F-431AA3539D74Q35067988-35A85E58-48B5-4D1B-B6F8-20FEF981BD84Q36224827-BE5BE08E-49A5-46B7-B3C0-AC480A6764A8Q36254566-70D38BF2-C746-4B38-899A-4F619D929D96Q36413501-6E6641F6-9FDB-47AE-A27E-91EF6F92621AQ37373624-D4749D1B-EF25-4A1B-8B88-7FA1867D1CCEQ37597751-B6A9FD42-4F20-4E0D-83ED-C0790FB5D6B3Q37705811-24171416-42FF-4CCB-843E-42C8A93BAC82Q38237446-7003A17B-3179-49D8-88BF-615D563821A6Q38253374-2B8183F8-4706-42E8-B6F1-87E219640C12Q38264923-2FDC624B-3202-4EB4-AFAD-3FB2099E9CD7Q38689170-67802CF4-D323-4826-A8FA-D1937E99A60FQ38767024-172CCD7A-4141-4FE3-AAA8-562E6F26A551Q38781794-6C485DE4-F764-430E-B21D-65154A4E7BF7Q38846167-7A459C8D-8110-447E-A238-E0FB8CF354A3Q38879778-DE0F5C78-9625-4140-B9E7-AD1525C2E197Q38963137-A091D048-5B93-4846-8254-6C1DEC120796Q39021977-AD5F832F-C646-4E6D-BFE1-A9943FC4A2DCQ39667223-07BA92B5-FD8B-4AD9-A944-DB2CCBD69D6CQ39923951-38730315-1519-479F-80A8-FF41293DB4CDQ40856384-F18FC53F-A0C0-4F5F-AD6E-3739368439FFQ42047385-920BAF59-0A9C-4E9B-BA6F-8EAE6431A98DQ42178342-25A5A321-B476-4845-8553-A2F8A4916907Q42317497-BA6F4317-FD01-47F8-8B8C-07E0428F64D7Q42421291-B6F834E4-BAA8-49C5-8366-9DECE3D3EC25Q44404066-C8BA85A7-5F19-42C0-845F-C3A85CE3BEA0Q44847917-3D65E36B-4AB5-40E6-B7EE-C40A01E7ABDDQ47149175-AF3AC722-38B9-4E16-8374-9387B8E4EDC1Q49313057-E1CA8744-19CF-4B96-A866-6190407CEFF1Q51735874-ED253181-4748-440C-8961-BA07419E63F3Q52838137-8F62DC80-EBB2-4932-A509-2C00587C3AA5
P2860
Biological and clinical relevance of miRNA expression signatures in primary plasma cell leukemia.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Biological and clinical releva ...... primary plasma cell leukemia.
@en
Biological and clinical releva ...... primary plasma cell leukemia.
@nl
type
label
Biological and clinical releva ...... primary plasma cell leukemia.
@en
Biological and clinical releva ...... primary plasma cell leukemia.
@nl
prefLabel
Biological and clinical releva ...... primary plasma cell leukemia.
@en
Biological and clinical releva ...... primary plasma cell leukemia.
@nl
P2093
P50
P1476
Biological and clinical releva ...... n primary plasma cell leukemia
@en
P2093
Antonietta Falcone
Fortunato Morabito
Francesco Di Raimondo
Gabriella Bianchino
Giacomo Tuana
Maria E Gallo Cantafio
Maria Teresa Di Martino
Maria Teresa Petrucci
Mario Boccadoro
Marta Lionetti
P304
P356
10.1158/1078-0432.CCR-12-2043
P407
P50
P577
2013-04-23T00:00:00Z